Author

Sarita Barsainya

Observed names: Barsainya, Sarita, Sarita G. Barsainya

Institution: Novartis (India)

Observed institution: Novartis (India)

OpenAlex ID: A5019942591

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria

2021 · Esther K Schmitt, Gilles Ndayisaba, et al. · Clinical Infectious Diseases · 88

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

2021 · Gilles Ndayisaba, Adoke Yeka, et al. · Malaria Journal · 27

Therapeutic equivalence of vildagliptin 100 mg once daily modified release to 50 mg twice daily immediate release formulation: An open-label, randomized, two-period, single- and multiple-dose, 6-day crossover study

2022 · Ramachandra Sangana, Hemant Mittal, et al. · Diabetes & Metabolic Syndrome Clinical Research & Reviews · 9

S21-5 to Study the Role of H2s in the Initial Stage of Atherosclerosis

2007 · Sarita G. Barsainya, Gaurang B. Shah · International Journal of Cardiology · 1

Works count: 6

Citation count: 125

H-index: 3

I10-index: 2